Skip to main content
. 2022 May 13;238:114458. doi: 10.1016/j.ejmech.2022.114458

Fig. 7.

Fig. 7

The anti-SARS-CoV-2 activity and cytotoxicity of the peptidomimetic inhibitors 10b (A), 10c (B), 10g (C), 10i (D), 14d (E), 17i (F). As green line, the peptidomimetic inhibitors were screened for viral inhibitory activity in Vero E6 cells. Vero E6 cells were infected with SARS-CoV-2 at 0.01 multiplicity of infection (MOI) in the presence of different compounds, and viral RNA in the supernatant was quantified by qRT-PCR at 24 hpi. As red line, the dose-dependent anti-SARS-CoV-2 activity of selected compounds were determined by serial dilution. Vero E6 cells were treated with series diluted compounds, and infected with SARS-CoV-2 virus at a MOI of 0.01. Viral RNA in supernatant was quantified by qRT-PCR and the inhibition rate was calculated by comparing with the viral RNA level in the DMSO control group. The cell viability was tested by MTT assay after compounds treatment. The cell viability was calculated as the percentage of the absorption value of the compounds treated cells to that of the DMSO treated cells. The cell viability of DMSO treated cells was set as 100%, and higher value of cell viability indicates less cytotoxicity.